×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)

Compare Coronavirus Therapeutics Stocks

Enter up to ten stock symbols separated by a comma or space (ex. REGN,GILD,SRNE,AMGN,ABBV,GSK,LLY).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
REGN
Regeneron Pharmaceuticals
$683.44
-1.1%
$681.71
$492.13
$747.42
$74.18B0.25700,342 shs523,508 shs
GILD
Gilead Sciences
$64.47
-0.8%
$61.53
$57.19
$74.12
$80.87B0.3810.10 million shs5.65 million shs
SRNE
Sorrento Therapeutics
$1.54
+6.9%
$1.86
$1.15
$11.07
$598.98M2.438.53 million shs5.61 million shs
AMGN
Amgen
$253.05
+0.0%
$244.67
$198.64
$258.45
$135.18B0.583.15 million shs2.22 million shs
ABBV
AbbVie
$150.57
-0.9%
$157.53
$105.56
$175.91
$266.07B0.837.81 million shs6.63 million shs
GSK
GlaxoSmithKline
$44.42
-1.2%
$44.57
$37.80
$46.97
$112.91B0.645.13 million shs6.37 million shs
LLY
Eli Lilly and
$313.46
+2.1%
$294.44
$195.50
$314.00
$297.84B0.42.93 million shs3.27 million shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
REGN
Regeneron Pharmaceuticals
+0.71%+4.81%+0.08%+13.30%+38.72%
GILD
Gilead Sciences
+1.03%+2.83%+3.77%+7.26%-1.84%
SRNE
Sorrento Therapeutics
-0.69%-4.64%-18.18%-44.83%-79.60%
AMGN
Amgen
+0.44%+3.71%+0.33%+15.39%+4.55%
ABBV
AbbVie
+1.91%-0.31%-2.78%+4.61%+32.65%
GSK
GlaxoSmithKline
-0.07%+3.07%-0.38%+9.18%+16.32%
LLY
Eli Lilly and
+0.34%+4.00%+7.65%+26.30%+54.11%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
REGN
Regeneron Pharmaceuticals
2.34 of 5 Stars
1.34.50.03.32.5
GILD
Gilead Sciences
3.05 of 5 Stars
3.15.03.32.51.3
SRNE
Sorrento Therapeutics
1.83 of 5 Stars
3.55.00.00.00.6
AMGN
Amgen
2.62 of 5 Stars
1.14.93.32.51.3
ABBV
AbbVie
2.78 of 5 Stars
2.34.94.22.50.0
GSK
GlaxoSmithKline
1.37 of 5 Stars
0.03.72.50.00.6
LLY
Eli Lilly and
2.95 of 5 Stars
1.44.83.33.31.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
REGN
Regeneron Pharmaceuticals
2.65
Buy$720.115.37% Upside
GILD
Gilead Sciences
2.29
Hold$72.2112.01% Upside
SRNE
Sorrento Therapeutics
3.00
Buy$20.001,198.70% Upside
AMGN
Amgen
2.14
Hold$242.21-4.28% Downside
ABBV
AbbVie
2.56
Buy$159.756.10% Upside
GSK
GlaxoSmithKline
2.10
Hold$1,850.004,064.79% Upside
LLY
Eli Lilly and
2.83
Buy$307.94-1.76% Downside

Current Analyst Ratings

Latest Coronavirus Therapeutics Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2022
REGN
Regeneron Pharmaceuticals
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$738.00
5/23/2022
GILD
Gilead Sciences
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$68.00
5/23/2022
AMGN
Amgen
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$256.00
5/23/2022
ABBV
AbbVie
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$140.00
5/23/2022
LLY
Eli Lilly and
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$341.00
5/16/2022
GILD
Gilead Sciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral$73.00 ➝ $69.00
5/10/2022
AMGN
Amgen
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$202.00 ➝ $208.00
5/6/2022
ABBV
AbbVie
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$150.00
5/3/2022
AMGN
Amgen
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform$285.00
5/2/2022
ABBV
AbbVie
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$165.00 ➝ $200.00
5/2/2022
LLY
Eli Lilly and
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$315.00 ➝ $356.00
(Data available from 5/26/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
REGN
Regeneron Pharmaceuticals
$16.07B4.62$84.06 per share8.13$183.48 per share3.72
GILD
Gilead Sciences
$27.31B2.96$9.13 per share7.06$15.88 per share4.06
SRNE
Sorrento Therapeutics
$52.90M11.32N/AN/A$0.58 per share2.66
AMGN
Amgen
$25.98B5.20$24.43 per share10.36$1.71 per share147.98
ABBV
AbbVie
$56.20B4.73$17.53 per share8.59$9.23 per share16.31
GSK
GlaxoSmithKline
$46.91B2.41$2.95 per share15.06$11.95 per share3.72
LLY
Eli Lilly and
$28.32B10.52$10.28 per share30.48$9.96 per share31.47

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
REGN
Regeneron Pharmaceuticals
$8.08B$70.609.6815.491.2648.06%50.10%36.73%8/4/2022 (Estimated)
GILD
Gilead Sciences
$6.23B$3.5818.0110.360.4516.43%44.98%13.89%8/4/2022 (Estimated)
SRNE
Sorrento Therapeutics
-$428.33M-$1.23N/A0.18N/A-826.96%-259.47%-52.29%6/1/2022 (Estimated)
AMGN
Amgen
$5.89B$10.1624.9113.331.7121.75%165.95%16.30%8/2/2022 (Estimated)
ABBV
AbbVie
$11.54B$6.9721.6012.754.2622.00%159.31%15.73%7/29/2022 (Estimated)
GSK
GlaxoSmithKline
$6.03B$2.7716.0413.181.9314.03%28.13%7.57%7/27/2022 (Estimated)
LLY
Eli Lilly and
$5.58B$6.7546.4432.792.2720.90%97.58%16.92%8/2/2022 (Estimated)

Latest Coronavirus Therapeutics Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/4/2022Q1 2022
REGN
Regeneron Pharmaceuticals
$9.37$11.49+$2.12$14.37$2.69 billion$2.97 billion    
4/29/20223/31/2022
ABBV
AbbVie
$3.14$3.16+$0.02N/A$13.61 billion$13.36 billion      
4/28/2022Q1 2022
GILD
Gilead Sciences
$1.77$2.12+$0.35$4.22$6.28 billion$6.59 billion      
4/28/2022Q1 2022
LLY
Eli Lilly and
$2.32$2.62+$0.30$3.14$7.29 billion$7.81 billion      
4/27/2022Q1 2022
AMGN
Amgen
$4.22$4.25+$0.03$5.82$6.09 billion$6.24 billion    
4/27/2022Q1 2022
GSK
GlaxoSmithKline
$0.77$0.88+$0.11$0.80$11.97 billion$13.12 billion
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
REGN
Regeneron Pharmaceuticals
N/AN/AN/AN/AN/A
GILD
Gilead Sciences
$2.924.53%+7.60%81.56%7 Years
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
AMGN
Amgen
$7.763.07%+10.10%76.38%11 Years
ABBV
AbbVie
$5.643.75%+10.37%80.92%50 Years
GSK
GlaxoSmithKline
$1.373.08%N/A49.46%N/A
LLY
Eli Lilly and
$3.921.25%+14.81%58.07%8 Years

Latest Coronavirus Therapeutics Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2022
GSK
GlaxoSmithKline
quarterly$0.3496304.4%5/19/20225/20/20227/1/2022
5/2/2022
GILD
Gilead Sciences
quarterly$0.734.8%6/14/20226/15/20226/29/2022
5/2/2022
LLY
Eli Lilly and
quarterly$0.981.35%5/13/20225/16/20226/10/2022
3/2/2022
AMGN
Amgen
quarterly$1.943.39%5/16/20225/17/20226/8/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
REGN
Regeneron Pharmaceuticals
0.14
4.76
4.09
GILD
Gilead Sciences
1.31
1.48
1.30
SRNE
Sorrento Therapeutics
0.42
1.62
1.18
AMGN
Amgen
39.31
1.44
1.09
ABBV
AbbVie
3.89
0.82
0.71
GSK
GlaxoSmithKline
1.29
1.19
0.95
LLY
Eli Lilly and
1.60
1.27
0.98

Ownership

Institutional Ownership

CompanyInstitutional Ownership
REGN
Regeneron Pharmaceuticals
83.83%
GILD
Gilead Sciences
80.16%
SRNE
Sorrento Therapeutics
27.04%
AMGN
Amgen
79.01%
ABBV
AbbVie
67.03%
GSK
GlaxoSmithKline
32.76%
LLY
Eli Lilly and
82.75%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
REGN
Regeneron Pharmaceuticals
10,368108.54 million95.69 millionOptionable
GILD
Gilead Sciences
14,4001.25 billion1.25 billionOptionable
SRNE
Sorrento Therapeutics
799388.95 million376.11 millionOptionable
AMGN
Amgen
24,200534.20 million531.74 millionOptionable
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
GSK
GlaxoSmithKline
90,0962.54 billion2.29 billionOptionable
LLY
Eli Lilly and
35,000950.16 million949.02 millionOptionable

Coronavirus Therapeutics Stocks Headlines

SourceHeadline
Lilly plans $2.1B investment in two new Boone County manufacturing sitesLilly plans $2.1B investment in two new Boone County manufacturing sites
wishtv.com - May 26 at 4:20 PM
Lilly to expand, add jobs with two new factories in IndianaLilly to expand, add jobs with two new factories in Indiana
biopharmadive.com - May 26 at 4:20 PM
Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells $12,855,409.50 in StockEli Lilly and Company (NYSE:LLY) Major Shareholder Sells $12,855,409.50 in Stock
marketbeat.com - May 26 at 12:20 PM
Eli Lilly To Spend $2.1 Billion On New Drug-Making Plants In IndianaEli Lilly To Spend $2.1 Billion On New Drug-Making Plants In Indiana
khn.org - May 26 at 11:20 AM
Dow Jones Rallies As Nvidia Slashes Losses; Twitter Jumps As Musk Raises FinancingDow Jones Rallies As Nvidia Slashes Losses; Twitter Jumps As Musk Raises Financing
finance.yahoo.com - May 26 at 11:20 AM
What You Need To Know About Eli Lilly and Companys (NYSE:LLY) Investor CompositionWhat You Need To Know About Eli Lilly and Company's (NYSE:LLY) Investor Composition
finance.yahoo.com - May 26 at 11:20 AM
Lilly plans $2.1B sites in IndianaLilly plans $2.1B sites in Indiana
djc.com - May 26 at 4:36 AM
Lilly Endowment Inc Sells 118,856 Shares of Eli Lilly and Company (NYSE:LLY) StockLilly Endowment Inc Sells 118,856 Shares of Eli Lilly and Company (NYSE:LLY) Stock
americanbankingnews.com - May 26 at 4:10 AM
Eli Lilly to construct new manufacturing sites in IndianaEli Lilly to construct new manufacturing sites in Indiana
wane.com - May 25 at 11:36 PM
Lilly To Invest $2.1 Bln In New Manufacturing Sites In IndianaLilly To Invest $2.1 Bln In New Manufacturing Sites In Indiana
nasdaq.com - May 25 at 11:36 PM
Eli Lilly and (NYSE:LLY) Upgraded at StockNews.comEli Lilly and (NYSE:LLY) Upgraded at StockNews.com
marketbeat.com - May 25 at 10:07 PM
Eli Lilly to invest $2.1 billion in new Boone County manufacturing sitesEli Lilly to invest $2.1 billion in new Boone County manufacturing sites
wrtv.com - May 25 at 6:35 PM
Eli Lilly to invest $2.1 billion in 2 new Lebanon manufacturing sitesEli Lilly to invest $2.1 billion in 2 new Lebanon manufacturing sites
wthr.com - May 25 at 6:35 PM
Eli Lilly and Company to assist insulin production in BangladeshEli Lilly and Company to assist insulin production in Bangladesh
newagebd.net - May 25 at 6:35 PM
Eli Lilly announces $2.1 billion manufacturing expansion in Boone CountyEli Lilly announces $2.1 billion manufacturing expansion in Boone County
indystar.com - May 25 at 6:35 PM
Eli Lilly will build $2 billion plant in Boone Countys new industrial parkEli Lilly will build $2 billion plant in Boone County's new industrial park
news.yahoo.com - May 25 at 6:35 PM
Eli Lilly allocates $2.1 billion to expand production footprint in IndianaEli Lilly allocates $2.1 billion to expand production footprint in Indiana
seekingalpha.com - May 25 at 6:35 PM
Eli Lilly to invest $2.1 billion in Lebanon manufacturing sitesEli Lilly to invest $2.1 billion in Lebanon manufacturing sites
msn.com - May 25 at 6:35 PM
Eli Lilly announces $2.1 billion dollar expansion in IndianaEli Lilly announces $2.1 billion dollar expansion in Indiana
wfyi.org - May 25 at 6:35 PM
Lilly plans new $2.1 billion manufacturing sites in IndianaLilly plans new $2.1 billion manufacturing sites in Indiana
msn.com - May 25 at 6:35 PM
Lilly plans to invest $2.1 billion in new manufacturing sites in IndianaLilly plans to invest $2.1 billion in new manufacturing sites in Indiana
finance.yahoo.com - May 25 at 6:35 PM
Lilly proposes two new manufacturing sites in IndianaLilly proposes two new manufacturing sites in Indiana
finance.yahoo.com - May 25 at 6:35 PM
Why North Carolinas hefty economic incentives dont guarantee big salariesWhy North Carolina's hefty economic incentives don't guarantee big salaries
finance.yahoo.com - May 25 at 10:11 AM
Dow Jones Reverses Ahead Of Fed Minutes; Nvidia Earnings NextDow Jones Reverses Ahead Of Fed Minutes; Nvidia Earnings Next
finance.yahoo.com - May 25 at 10:11 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.